Current status of gene therapy in melanoma treatment

被引：4

作者：

Wang, Yonglu ^{[1
,2
]}

You, Wei ^{[1
]}

Li, Xueming ^{[3
,4
]}

机构：

[1] Nanjing Tech Univ, Coll Pharm, Nanjing, Peoples R China

[2] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada

[3] Nanjing Bestform Pharmaceut Technol Co Ltd, Nanjing, Peoples R China

[4] Nanjing Tech Univ, Postgrad Dept, Nanjing, Peoples R China

来源：

BIOCELL | 2020年 / 44卷 / 02期

关键词：

Gene therapy; Melanoma; Viral delivery system; Nanoparticles; TUMOR-SUPPRESSOR; GM-CSF; CANCER; ONCOGENES; INFLAMMATION; DELIVERY; PEPTIDE;

D O I：

10.32604/biocell.2020.09023

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Melanoma is the deadliest type of skin cancer and which has a high ability of metastasis. Surgery is an effective method to treat I or II stage melanoma patients. However, there are few treatment options for metastatic melanoma. Gene therapy is one of the attractive options and is considered as the future direction for treating melanoma. This review mainly discusses the properties and challenges of the various gene therapies in melanoma, especially the delivery systems and gene targeting.

引用

页码：167 / 174

页数：8

共 46 条

[1] The CD40/CD40 Ligand System Linking Inflammation With Atherothrombosis [J].

Antoniades, Charalambos ;

Bakogiannis, Constantinos ;

Tousoulis, Dimitris ;

Antonopoulos, Alexios S. ;

Stefanadis, Christodoulos .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (08) :669-677

[2] New strategies in melanoma therapy: can nanoparticles overcome chemoresistance? [J].

Badea, Ildiko .

NANOMEDICINE, 2017, 12 (14) :1623-1626

[3] Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells [J].

Bak, S. Peter ;

Barnkob, Mike Stein ;

Bai, Ailin ;

Higham, Eileen M. ;

Wittrup, K. Dane ;

Chen, Jianzhu .

JOURNAL OF IMMUNOLOGY, 2012, 189 (04) :1708-1716

[4] Nanoemulsion-templated polylelectrolyte multifunctional nanocapsules for DNA entrapment and bioimaging [J].

Bazylinska, Urszula ;

Saczko, Jolanta .

COLLOIDS AND SURFACES B-BIOINTERFACES, 2016, 137 :191-202

[5] Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients [J].

Bol, Kalijn F. ;

Mensink, Hanneke W. ;

Aarntzen, Erik H. J. G. ;

Schreibelt, Gerty ;

Keunen, Jan E. E. ;

Coulie, Pierre G. ;

De Klein, Annelies ;

Punt, Cornelis J. A. ;

Paridaens, Dion ;

Figdor, Carl G. ;

De Vries, I. Jolanda M. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 158 (05) :939-947

[6] The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) [J].

Breitbach, Caroline J. ;

Bell, John C. ;

Hwang, Tae-Ho ;

Kirn, David H. ;

Burke, James .

ONCOLYTIC VIROTHERAPY, 2015, 4 :25-31

[7] Targeting CD20 takes the backseat in CLL [J].

Byrd, John C. .

BLOOD, 2019, 133 (10) :1003-1004

[8] Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? [J].

Carlino, Matteo S. ;

Long, Georgina V. .

CLINICAL CANCER RESEARCH, 2016, 22 (16) :3992-3998

[9] Intracellular DNA Cargo Release from a Gold Nanoparticle Modulated by the Nature of the Surface Coupling Functionality [J].

Carnevale, Kate J. F. ;

Strouse, Geoffrey F. .

BIOCONJUGATE CHEMISTRY, 2018, 29 (10) :3429-3440

[10] Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation [J].

Chen, Jianzhou ;

Cao, Yunhong ;

Markelc, Bostjan ;

Kaeppler, Jakob ;

Vermeer, Jenny A. F. ;

Muschel, Ruth J. .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10) :4224-4238

← 1 2 3 4 5 →